Titre:
  • Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Auteur:Colleoni, Marco Angelo; Luo, Weixiu; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Hitre, Erika; Graas, Marie-Pascale; Simoncini, Edda; Kamby, Claus; Thompson, Alastair M; Loibl, Sibylle; Gavilá, Joaquín; Kuroi, Katsumasa; Marth, Christian; Müller, Bettina; O'Reilly, Seamus; Di Lauro, Vincenzo; Gombos, Andrea; Ruhstaller, Thomas; Burstein, Harold; Ribi, Karin; Bernhard, Jürg; Viale, Giuseppe; Maibach, Rudolf; Rabaglio-Poretti, Manuela; Gelber, Richard D; Coates, Alan A.S.; Di Leo, Angelo; Regan, Meredith; Goldhirsch, Aron; SOLE Investigators,
Informations sur la publication:Lancet oncology, 19, 1, page (127-138)
Statut de publication:Publié, 2018
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Aged
Antineoplastic Agents -- administration & dosage -- adverse effects
Aromatase Inhibitors -- administration & dosage -- adverse effects
Biomarkers, Tumor -- analysis
Breast Neoplasms -- chemistry -- drug therapy -- mortality -- pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Drug Administration Schedule
Female
Humans
Letrozole
Middle Aged
Nitriles -- administration & dosage -- adverse effects
Postmenopause
Receptor, ErbB-2 -- analysis
Receptors, Estrogen -- analysis
Receptors, Progesterone -- analysis
Time Factors
Treatment Outcome
Triazoles -- administration & dosage -- adverse effects
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(17)30715-5
info:pii/S1470-2045(17)30715-5
info:pmid/29158011